Lovastatin-induced decrease of intracellular cholesterol level attenuates fibroblast-to-myofibroblast transition in bronchial fibroblasts derived from asthmatic patients
- PMID: 23485731
- DOI: 10.1016/j.ejphar.2013.02.023
Lovastatin-induced decrease of intracellular cholesterol level attenuates fibroblast-to-myofibroblast transition in bronchial fibroblasts derived from asthmatic patients
Abstract
Chronic inflammation of the airways and structural changes in the bronchial wall are basic hallmarks of asthma. Human bronchial fibroblasts derived from patients with diagnosed asthma display in vitro predestination towards TGF-β-induced fibroblast-to-myofibroblast transition (FMT), a key event in the bronchial wall remodelling. Statins inhibit 3-hydroxymethyl-3-glutaryl coenzyme A reductase, a key enzyme in the cholesterol synthesis pathway and are widely used as antilipidemic drugs. The pleiotropic anti-inflammatory effects of statins, independent of their cholesterol-lowering capacity, are also well established. Since commonly used anti-asthmatic drugs do not reverse the structural remodelling of the airways and statins have tentative anti-asthmatic activity, we have studied the effect of lovastatin on FMT in populations of human bronchial fibroblasts derived from asthmatic patients. We demonstrate that the intensity of FMT induced by TGF-β1 was strongly and dose-dependently attenuated by lovastatin. Furthermore, we show that neither the suppression of prenylation of signalling proteins nor the effect on reactive oxygen species formation are important for lovastatin-induced inhibition of myofibroblast differentiation. On the other hand, we show that a squalene synthase inhibitor, zaragozic acid A, reduced the TGF-β1-induced FMT to an extent comparable to lovastatin effect. Additionally we demonstrate that in bronchial fibroblast populations, both inhibitors (lovastatin and zaragozic acid A) attenuate the TGF-β1-induced Smad2 nuclear translocation in a manner dependent on intracellular cholesterol level. Our data suggest that statins can directly, by decrease of intracellular cholesterol level, affect basic cell signalling events crucial for asthmatic processes and potentially prevent perilous bronchial wall remodelling associated with intensive myofibroblast formation.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Enhanced asthma-related fibroblast to myofibroblast transition is the result of profibrotic TGF-β/Smad2/3 pathway intensification and antifibrotic TGF-β/Smad1/5/(8)9 pathway impairment.Sci Rep. 2020 Oct 5;10(1):16492. doi: 10.1038/s41598-020-73473-7. Sci Rep. 2020. PMID: 33020537 Free PMC article.
-
Transition of asthmatic bronchial fibroblasts to myofibroblasts is inhibited by cell-cell contacts.Respir Med. 2011 Oct;105(10):1467-75. doi: 10.1016/j.rmed.2011.04.009. Epub 2011 Jul 29. Respir Med. 2011. PMID: 21802932
-
Connexin43 Controls the Myofibroblastic Differentiation of Bronchial Fibroblasts from Patients with Asthma.Am J Respir Cell Mol Biol. 2017 Jul;57(1):100-110. doi: 10.1165/rcmb.2015-0255OC. Am J Respir Cell Mol Biol. 2017. PMID: 28245135
-
Fibroblast-to-myofibroblast transition in bronchial asthma.Cell Mol Life Sci. 2018 Nov;75(21):3943-3961. doi: 10.1007/s00018-018-2899-4. Epub 2018 Aug 12. Cell Mol Life Sci. 2018. PMID: 30101406 Free PMC article. Review.
-
Transforming growth factor-beta1 in asthmatic airway smooth muscle enlargement: is fibroblast growth factor-2 required?Clin Exp Allergy. 2010 May;40(5):710-24. doi: 10.1111/j.1365-2222.2010.03497.x. Clin Exp Allergy. 2010. PMID: 20447083 Review.
Cited by
-
Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.Drug Des Devel Ther. 2015 Sep 18;9:5269-75. doi: 10.2147/DDDT.S90016. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26425076 Free PMC article.
-
Enhanced asthma-related fibroblast to myofibroblast transition is the result of profibrotic TGF-β/Smad2/3 pathway intensification and antifibrotic TGF-β/Smad1/5/(8)9 pathway impairment.Sci Rep. 2020 Oct 5;10(1):16492. doi: 10.1038/s41598-020-73473-7. Sci Rep. 2020. PMID: 33020537 Free PMC article.
-
PPARδ Agonist GW501516 Suppresses the TGF-β-Induced Profibrotic Response of Human Bronchial Fibroblasts from Asthmatic Patients.Int J Mol Sci. 2023 Apr 23;24(9):7721. doi: 10.3390/ijms24097721. Int J Mol Sci. 2023. PMID: 37175437 Free PMC article.
-
Undifferentiated bronchial fibroblasts derived from asthmatic patients display higher elastic modulus than their non-asthmatic counterparts.PLoS One. 2015 Feb 13;10(2):e0116840. doi: 10.1371/journal.pone.0116840. eCollection 2015. PLoS One. 2015. PMID: 25679502 Free PMC article.
-
MYH9 Inhibition Suppresses TGF-β1-Stimulated Lung Fibroblast-to-Myofibroblast Differentiation.Front Pharmacol. 2021 Jan 13;11:573524. doi: 10.3389/fphar.2020.573524. eCollection 2020. Front Pharmacol. 2021. PMID: 33519439 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources